VPS4A

Calithera Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights

Retrieved on: 
Monday, August 15, 2022

SOUTH SAN FRANCISCO, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced its financial results for the second quarter ended June 30, 2022.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced its financial results for the second quarter ended June 30, 2022.
  • Calithera plans to share data from this trial by the first quarter of 2023.
  • Research and development expenses for the second quarter 2022 were $7.8 million, compared to $12.8 million in the same period prior year.
  • General and administrative expenses for the second quarter 2022 were $3.6 million, compared to $4.5 million in the same period prior year.

Calithera Biosciences Reports First Quarter 2022 Financial Results and Recent Highlights

Retrieved on: 
Tuesday, May 10, 2022

SOUTH SAN FRANCISCO, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced its financial results for the first quarter ended March 31, 2022.

Key Points: 
  • ET on Tuesday, May 10, 2022 --
    SOUTH SAN FRANCISCO, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced its financial results for the first quarter ended March 31, 2022.
  • We made significant headway in the transfer of mivavotinib and sapanisertib materials to Calithera during the first quarter and are well into site start-up activities.
  • Calithera anticipates the first patient enrolled in the second quarter of 2022.
  • Calithera anticipates the first patient enrolled in this study in the second quarter of 2022.

Calithera Presents Data Highlighting Discovery of Novel Series of Promising Synthetic Lethal Compounds

Retrieved on: 
Friday, April 8, 2022

SOUTH SAN FRANCISCO, Calif., April 08, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, shared new data today from the company’s preclinical synthetic lethality program. The findings, which are now available as an e-poster and will be presented live on April 11 at the American Association for Cancer Research (AACR) Annual Meeting 2022 (Abstract #1816), validate the synthetic lethal interaction between the gene paralogs vacuolar protein sorting-associated protein 4A (VPS4A) and 4B (VPS4B), and provide the first preclinical evidence supporting a newly discovered series of compounds designed to target these proteins for cancer treatment.

Key Points: 
  • Our discovery of a novel series of VPS4A inhibitors is an important validation of our platform, said Susan Molineaux, chief executive officer of Calithera.
  • Synthetic lethal interaction between genes occurs when inhibition of either gene alone does not alter cell viability, but simultaneous inhibition of both genes induces cell death.
  • Calithera is building a preclinical pipeline of synthetic lethality targets with a focus on paralog genes, which are pairs of genes that play redundant roles in essential cellular functions.
  • Utilizing the VPS4A and VPS4B paralog genes as targets, Calithera researchers identified a novel series of small molecule inhibitors.

Calithera Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights

Retrieved on: 
Thursday, March 31, 2022

SOUTH SAN FRANCISCO, Calif., March 31, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced its financial results for the fourth quarter and year ended December 31, 2021.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., March 31, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced its financial results for the fourth quarter and year ended December 31, 2021.
  • Research and development expenses for the fourth quarter of 2021 were $13.7 million, compared to $17.1 million for the same period last year.
  • General and administrative expenses for the fourth quarter of 2021 were $4.6 million, compared to $5.6 million for the same period last year.
  • Interest and other income, net for the fourth quarter of 2021 was none, compared to $0.1 million for the fourth quarter of 2020.

Calithera to Present Data Highlighting Newly Discovered Synthetic Lethal Target VPS4 at AACR 2022 Annual Meeting

Retrieved on: 
Tuesday, March 8, 2022

Membrane remodelling is an essential cellular function and loss of function of both VPS4 paralogs is lethal to cells.

Key Points: 
  • Membrane remodelling is an essential cellular function and loss of function of both VPS4 paralogs is lethal to cells.
  • The preclinical data demonstrate that VPS4A genetic inhibition in cell lines with loss of VPS4B preferentially showed profound death in cancer cells.
  • The data being shared at the AACR annual meeting suggest that inhibition of VPS4A is a promising approach to treat cancers across a wide variety of cancer types that harbor VPS4B deletions.
  • At AACR 2022, Calithera will report the discovery of a series of novel, small-molecule VPS4A inhibitors which have potential in the treatment of VPS4B-deleted tumors.